Orris
attachment
attachment

Explain the origin of quinolones

Reading File
analyse_media
Finding Sources
Finding Sources
Searching the Web

history discovery of nalidixic acid George Lesher chloroquine synthesis quinolone antibiotics origin

Origin of Quinolones

The accidental discovery
Quinolones originated from antimalarial research, not antibacterial research. In 1962, George Lesher and coworkers at Sterling Drug (Sterling-Winthrop Research Institute) were trying to synthesize chloroquine, an antimalarial drug. During this synthesis process, they isolated a by-product/impurity in a distillate that turned out to have antibacterial activity. That compound was nalidixic acid, the first quinolone - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 251; Lippincott Illustrated Reviews Pharmacology.
This traces back further to the wartime and postwar effort to develop synthetic antimalarials as substitutes for quinine (derived from cinchona bark). Chloroquine itself had been discovered by Hans Andersag in 1934 while working on quinine-based structures. Sterling's chemists were extending this line of work when the nalidixic acid impurity turned up, essentially a "happy accident" in drug discovery.
Structure
Nalidixic acid is chemically a naphthyridone (1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid), closely related to the quinolone nucleus. It became the prototype for the entire quinolone class, and its core 4-oxo-quinoline/naphthyridine-carboxylic acid scaffold is what all later quinolones and fluoroquinolones were built from - matching the structure shown in your slide.
Clinical introduction and evolution
  • 1962-1964: Nalidixic acid discovered and clinically introduced by Sterling Drug in the US, used for uncomplicated urinary tract infections caused by gram-negative organisms. This marks the 1st generation of quinolones.
  • Over the following two decades, chemists modified the quinolone nucleus systematically - adding substituents at various ring positions - which:
    • Broadened the antibacterial spectrum (adding gram-positive and Pseudomonas coverage)
    • Improved pharmacokinetics (absorption, half-life, tissue penetration)
    • Improved chemical stability
  • The key breakthrough was the addition of a fluorine atom at the C-6 position of the quinolone ring in the 1980s, producing the fluoroquinolones (norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, etc.). These were far more potent, had broader spectra, and better oral bioavailability than nalidixic acid - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 251.
  • This progressive modification is why later generations (2nd, 3rd, 4th) are described in your slide as gaining increasing gram-positive, atypical, and anaerobic/mycobacterial coverage while retaining the core naphthyridone/quinolone scaffold inherited from nalidixic acid.
Summary of the lineage Cinchona bark (quinine) → synthetic antimalarials (chloroquine, 1934) → accidental isolation of nalidixic acid as a chloroquine synthesis by-product (Lesher et al., 1962) → 1st generation quinolones → fluorination and structural optimization → 2nd/3rd/4th generation fluoroquinolones in clinical use today.
A brief evidence check: I ran a recent literature scan (systematic reviews/meta-analyses, last 2 years) specifically on this historical/origin question and found no new results, which is expected since this is settled pharmacological history rather than an active clinical evidence question. No contradicting or updating evidence to flag.
attachment
attachment

Explain

Finding Sources
Finding Sources
Searching the Web

quinolone generations classification 1st 2nd 3rd 4th generation fluoroquinolones mechanism of action DNA gyrase topoisomerase IV

Explanation: Quinolone Generations & Mechanism of Action

1. Generation classification (with a correction to the slide)

Your slide labels the 1st generation as "fluoroquinolones" - this is a common slide error worth flagging. True fluoroquinolones only begin with the 2nd generation, when a fluorine atom was added at the C-6 (or C7) position of the quinolone nucleus. The 1st generation drugs (nalidixic acid, cinoxacin, oxolinic acid) are non-fluorinated quinolones - narrower-spectrum, used mainly for uncomplicated UTIs, with poor systemic/tissue penetration.
1st generation - quinolones (non-fluorinated)
  • Nalidixic acid, oxolinic acid, cinoxacin
  • Good activity against gram-negative aerobes (E. coli, Proteus, Klebsiella)
  • Essentially no gram-positive activity, no systemic infection use, urine-concentration only (UTIs)
2nd generation - fluoroquinolones
  • Ciprofloxacin, norfloxacin, ofloxacin, levofloxacin, enoxacin, lomefloxacin, fleroxacin, rufloxacin
  • Fluorine addition dramatically improved potency, tissue penetration, and half-life
  • Excellent gram-negative coverage (ciprofloxacin remains the most active against Pseudomonas aeruginosa), moderate gram-positive and some atypical/mycobacterial coverage
  • Used for UTIs, GI infections, respiratory infections, and systemic gram-negative infections
3rd generation
  • Levofloxacin (often placed here instead of 2nd gen depending on the textbook), gatifloxacin, grepafloxacin, pazufloxacin, sparfloxacin, tosufloxacin
  • Retain gram-negative/atypical activity but gain improved gram-positive coverage, notably Streptococcus pneumoniae - hence their use in community-acquired pneumonia ("respiratory quinolones")
4th generation
  • Moxifloxacin, gemifloxacin, trovafloxacin, clinafloxacin
  • Further improved gram-positive and anaerobic coverage, plus continued gram-negative and atypical/mycobacterial activity
  • Moxifloxacin is the most clinically relevant survivor of this group (respiratory infections, some intra-abdominal use because of anaerobic coverage); several others (trovafloxacin, grepafloxacin, gatifloxacin in some markets) were withdrawn or restricted due to toxicity (hepatotoxicity, dysglycemia, QT prolongation).
The unifying trend across generations: each round of chemical modification to the quinolone/naphthyridone core expanded spectrum outward (gram-negative → gram-positive → atypicals → anaerobes/mycobacteria) while also improving pharmacokinetics (oral bioavailability, tissue penetration, half-life) - Lippincott Illustrated Reviews Pharmacology; Katzung's Basic and Clinical Pharmacology.

2. Mechanism of action

Quinolones are bactericidal and work by blocking bacterial DNA synthesis through inhibition of two related type II topoisomerase enzymes:
  • DNA gyrase (topoisomerase II) - introduces negative supercoils ahead of the replication fork by cutting double-stranded DNA, passing another strand through, and resealing it. This relieves the positive torsional (supercoiling) stress generated as the replication/transcription machinery unwinds DNA. If gyrase is inhibited, the DNA cannot relax, replication and transcription stall, and the enzyme-DNA-drug complex becomes a "poison" that triggers double-strand breaks and cell death.
  • Topoisomerase IV - acts after replication to decatenate (separate) the two interlinked daughter chromosomes so they can be properly partitioned into the two daughter cells during division. Inhibiting this enzyme prevents chromosome segregation, again causing lethal DNA damage.
In gram-negative bacteria, DNA gyrase is usually the primary quinolone target; in gram-positive bacteria (like staphylococci and streptococci), topoisomerase IV tends to be the primary target - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 263-265; Katzung's Basic and Clinical Pharmacology, p. 2851.
Both enzymes are heterotetramers (gyrase = GyrA₂GyrB₂; topoisomerase IV = ParC₂ParE₂, with ParC/ParE homologous to GyrA/GyrB). Quinolones bind reversibly within the enzyme-DNA cleavage complex, trapping it in a state where the DNA remains cut - this "poisoned complex" is what actually kills the bacterium, rather than simple enzyme inhibition alone.
This dual-target mechanism (gyrase + topoisomerase IV) is also why resistance requires mutations in both target genes (gyrA/gyrB and parC/parE) to reach high-level resistance, plus plasmid-mediated resistance genes and efflux pump overexpression as additional mechanisms.

Quick corrections to note on your slide

  • "1st generation quinolones: Fluoroquinolones..." should read "1st generation quinolones (non-fluorinated)..." - nalidixic acid, cinoxacin, and oxolinic acid do not contain fluorine.
  • "nilidaxic acid" is a typo for nalidixic acid.
  • "grpafloxacin" / "Gatifloaxicin" are typos for grepafloxacin and gatifloxacin.
  • The mechanism-of-action paragraph on your slide is accurate and closely matches Katzung's Basic and Clinical Pharmacology wording.
I checked for recent systematic reviews/meta-analyses on quinolone mechanism/classification (2-year window) and found nothing that changes this foundational pharmacology - it remains standard, uncontested textbook material.
This is a shared conversation. Sign in to Orris to start your own chat.